Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background: There are numerous revisional surgery options for weight loss failure after Roux-en-Y Gastric Bypass. To date, there are no studies that assess the weight loss outcomes of single-stage endoscopic revision of the gastrojejunostomy (GJ) (TORe) in biliopancreatic (BP) limb distalization. We aimed to report our experience with single-stage TORe and distalization.

Methods: Sixteen patients (5 TORe and distalization, 6 TORe alone, 5 distalization alone) from 2021 to 2023 were included and retrospectively reviewed. The minimum follow-up time was 24 months. The alimentary limb was distalized to allow for a total common channel length of about 150 cm and the endoscopic suturing was used to bring the diameter of the GJ between 10 and 20 mm.

Results: The average preoperative BMI was 44.25 ± 8.8 kg/m with an average excess body weight of 54.16 ± 23.6 kg. The mean operative time for patients who had distalization with and without TORe was 128.4 ± 30.3 min. The mean total alimentary limb length (TALL) was 300 + 45.6 cm. Single-stage TORe and distalization showed higher mean %TWL (23.67 vs 19.92 vs 15.02) and %EWL (37.20 vs 30.72 vs 27) compared to TORe and distalization alone at 24-month follow-up, respectively. One patient required distalization reversal due to malnutrition. The rest of patients who underwent distalization showed minor nutritional deficiencies (Hemoglobin, Hematocrit, Vitamin A, and Copper) at the last follow-up. Preoperative comorbidities were reduced by 33.2%.

Conclusions: Endoscopic and surgical techniques for the management of weight loss failure after Roux-en-Y Gastric Bypass seem to be safe and effective. Single-stage TORe and distalization showed higher weight loss at 24-month follow-up.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00464-025-11846-7DOI Listing

Publication Analysis

Top Keywords

weight loss
20
tore distalization
20
gastric bypass
16
loss failure
12
failure roux-en-y
12
roux-en-y gastric
12
single-stage tore
12
distalization
10
management weight
8
tore
8

Similar Publications

Monoclonal gammopathy-associated myopathies (MGAMs) are rare yet treatable myopathies that occur in association with monoclonal gammopathies. These myopathies include light chain (AL) amyloidosis myopathy, sporadic late-onset nemaline myopathy (SLONM), scleromyxedema with associated myopathy, and newly reported monoclonal gammopathy-associated glycogen storage myopathy (MGGSM), including the vacuolar myopathy with monoclonal gammopathy and stiffness. All these 4 distinct subtypes of MGAMs typically present in patients aged 40 or older, frequently with a subacute onset of rapidly progressive proximal and axial muscle weakness.

View Article and Find Full Text PDF

Importance: Neonatal intensive care has advanced over recent decades, yet premature birth remains associated with increased neonatal mortality and morbidity.

Objective: To describe health service use, morbidity, and medication needs up to age 5 years in a contemporary cohort of children born preterm.

Design, Setting, And Participants: This population-based cohort study was conducted in British Columbia (BC), Canada, using health service and pharmacy data linked using provincial administrative databases.

View Article and Find Full Text PDF

The ameliorative effect of Lactiplantibacillus plantarum SCS2 on DSS-induced murine colitis.

Arch Microbiol

September 2025

School of Public Health, Chengdu University of Traditional Chinese Medicine, No. 1166, Liutai Avenue, Wenjiang District, Chengdu, 611137, Sichuan Province, China.

The inhibitory effects of Lactiplantibacillus plantarum on inflammatory responses are known, but its action mechanisms in oxidative stress, immunomodulation, and intestinal homeostasis remain of interest. Accordingly, we investigated the protective effects of Lactiplantibacillus plantarum SCS2 (L. plantarum SCS2) against sodium dextran sulfate (DSS)-induced colitis in mice as well as elucidated its impact on inflammation, oxidative stress, and intestinal microbiota.

View Article and Find Full Text PDF

Effects of Glucagon-Like Peptide-1 receptor agonists on bone health in people living with obesity.

Osteoporos Int

September 2025

Department of Rheumatology, Univ. Lille, CHU Lille, MABlab ULR 4490, 59000, Lille, France.

Medications like liraglutide 3.0 mg daily (Saxenda®; Novo Nordisk) and semaglutide 2.4 mg weekly (Wegovy®; Novo Nordisk), which are glucagon-like peptide-1 receptor agonists (GLP-1Ra), have been sanctioned for prolonged weight management in people living with obesity (PwO).

View Article and Find Full Text PDF